SE9302396D0 - A novel compound form - Google Patents

A novel compound form

Info

Publication number
SE9302396D0
SE9302396D0 SE19939302396A SE9302396A SE9302396D0 SE 9302396 D0 SE9302396 D0 SE 9302396D0 SE 19939302396 A SE19939302396 A SE 19939302396A SE 9302396 A SE9302396 A SE 9302396A SE 9302396 D0 SE9302396 D0 SE 9302396D0
Authority
SE
Sweden
Prior art keywords
novel compound
compound form
crystallinity
manufacture
useful
Prior art date
Application number
SE19939302396A
Other languages
English (en)
Swedish (sv)
Inventor
Aake *Kaellstroem Lars
Annelie *Nygren Monica
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9302396(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SE19939302396A priority Critical patent/SE9302396D0/xx
Application filed by Ab Astra filed Critical Ab Astra
Publication of SE9302396D0 publication Critical patent/SE9302396D0/xx
Priority to TW083105710A priority patent/TW504509B/zh
Priority to HR940385A priority patent/HRP940385B1/xx
Priority to IL11019094A priority patent/IL110190A/xx
Priority to SA94150058A priority patent/SA94150058B1/ar
Priority to IS4186A priority patent/IS2075B/is
Priority to MYPI94001774A priority patent/MY113274A/en
Priority to ZA944933A priority patent/ZA944933B/xx
Priority to EG40794A priority patent/EG21437A/xx
Priority to MA23567A priority patent/MA23257A1/fr
Priority to NZ268693A priority patent/NZ268693A/en
Priority to CN94192733A priority patent/CN1064680C/zh
Priority to SI9430414T priority patent/SI0707580T1/xx
Priority to HU9503873A priority patent/HU226861B1/hu
Priority to AU71981/94A priority patent/AU679766B2/en
Priority to EP94921154A priority patent/EP0707580B1/fr
Priority to JP50400595A priority patent/JP3635432B2/ja
Priority to SK22-96A priority patent/SK281230B6/sk
Priority to AT94921154T priority patent/ATE212628T1/de
Priority to DE0707580T priority patent/DE707580T1/de
Priority to DK94921154T priority patent/DK0707580T3/da
Priority to PT94921154T priority patent/PT707580E/pt
Priority to TNTNSN94079A priority patent/TNSN94079A1/fr
Priority to ES94921154T priority patent/ES2100136T3/es
Priority to DE69429774T priority patent/DE69429774T2/de
Priority to RU96102079A priority patent/RU2139868C1/ru
Priority to BR9406940A priority patent/BR9406940A/pt
Priority to UA96010059A priority patent/UA43343C2/uk
Priority to US08/313,342 priority patent/US5900424A/en
Priority to CZ199669A priority patent/CZ288933B6/cs
Priority to EP01117362A priority patent/EP1164132A3/fr
Priority to HK98109227.9A priority patent/HK1008329B/en
Priority to KR1019960700051A priority patent/KR100353783B1/ko
Priority to CA002166794A priority patent/CA2166794C/fr
Priority to YU43694A priority patent/YU49193B/sh
Priority to SG1996004887A priority patent/SG52464A1/en
Priority to PCT/SE1994/000680 priority patent/WO1995001977A1/fr
Priority to PL94312440A priority patent/PL175999B1/pl
Priority to MX9405217A priority patent/MX9405217A/es
Priority to EE9400405A priority patent/EE03127B1/xx
Priority to DZ940071A priority patent/DZ1792A1/fr
Priority to NO960068A priority patent/NO308702B1/no
Priority to FI960101A priority patent/FI114154B/fi
Priority to GR970300015T priority patent/GR970300015T1/el
Priority to JP2001293480A priority patent/JP3878826B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Contacts (AREA)
  • Conductive Materials (AREA)
  • Electroplating Methods And Accessories (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Powder Metallurgy (AREA)
  • Medicinal Preparation (AREA)
SE19939302396A 1993-07-09 1993-07-09 A novel compound form SE9302396D0 (sv)

Priority Applications (45)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form
TW083105710A TW504509B (en) 1993-07-09 1994-06-23 A novel form of magnesium omeprazole, its preparation process and pharmaceutical composition comprising the same
HR940385A HRP940385B1 (en) 1993-07-09 1994-07-01 Novel compound form
IL11019094A IL110190A (en) 1993-07-09 1994-07-01 Magnesium omeprazole with crystallinity higher than 70% process for its preparation and its use in the manufacture of medicaments for inhibiting gastric acid secretion and for obtaining gastric mucosa protective activity
SA94150058A SA94150058B1 (ar) 1993-07-09 1994-07-04 مركب ملح مغنسيوم الاومبرازول
IS4186A IS2075B (is) 1993-07-09 1994-07-05 Aðferð til að framleiða magnesíumómeprasól
MA23567A MA23257A1 (fr) 1993-07-09 1994-07-07 Nouvelle forme de compose demagnesium d'omeprazole etson utilisation .
EG40794A EG21437A (en) 1993-07-09 1994-07-07 Method for preparing magnesium omeprazole compounds useful for inhibiting gastric acid sectretion
MYPI94001774A MY113274A (en) 1993-07-09 1994-07-07 Omeprazole magnesium salt form
ZA944933A ZA944933B (en) 1993-07-09 1994-07-07 A novel compound form
PL94312440A PL175999B1 (pl) 1993-07-09 1994-07-08 Omeprazol magnezowy i sposób wytwarzania omeprazolu magnezowego oraz kompozycja farmaceutyczna go zawierająca
MX9405217A MX9405217A (es) 1993-07-09 1994-07-08 Proceso para la fabricacion de sal de magnesio de omeprazol, productoobtenido a partir del mismo y composicion farmaceutica que contiene dichoproducto.
PT94921154T PT707580E (pt) 1993-07-09 1994-07-08 Omeprazole magnesio
UA96010059A UA43343C2 (uk) 1993-07-09 1994-07-08 Магнієва сіль омепразолу, спосіб її одержання, фармацевтична композиція, спосіб лікування
SI9430414T SI0707580T1 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
HU9503873A HU226861B1 (en) 1993-07-09 1994-07-08 Magnesium salt of omeprazole
AU71981/94A AU679766B2 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
EP94921154A EP0707580B1 (fr) 1993-07-09 1994-07-08 Omeprazole de magnesium
JP50400595A JP3635432B2 (ja) 1993-07-09 1994-07-08 オメプラゾールマグネシウムの製法
SK22-96A SK281230B6 (sk) 1993-07-09 1994-07-08 Magnézium omeprazol, spôsob jeho výroby, farmaceutické prípravky s jeho obsahom a jeho použitie
AT94921154T ATE212628T1 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
DE0707580T DE707580T1 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
DK94921154T DK0707580T3 (da) 1993-07-09 1994-07-08 Magnesiumomeprazol
NZ268693A NZ268693A (en) 1993-07-09 1994-07-08 Magnesium omeprazole having a degree of crystallinity greater than 70%
TNTNSN94079A TNSN94079A1 (fr) 1993-07-09 1994-07-08 Une nouvelle forme de compose
ES94921154T ES2100136T3 (es) 1993-07-09 1994-07-08 Omeprazol de magnesio.
DE69429774T DE69429774T2 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
RU96102079A RU2139868C1 (ru) 1993-07-09 1994-07-08 Магниевая соль омепразола, способ ее получения, фармацевтическая композиция, способ лечения
BR9406940A BR9406940A (pt) 1993-07-09 1994-07-08 Magnésio-omeprazol processo para a preparação de magnésio-omeprazol composição farmacêutica formulação farmacêutica para a administração oral forumulação de tablete uso do magnesio-omeprazol processo para a inibição da secreção de ácido gástrico em mamiferos e no homem e processo para o tratamento das doenças relacionadas com o ácido gastrico em mamiferos e no homem
CN94192733A CN1064680C (zh) 1993-07-09 1994-07-08 奥美拉唑镁的制备方法
US08/313,342 US5900424A (en) 1993-07-09 1994-07-08 Omeprazole magnesium salt form
CZ199669A CZ288933B6 (cs) 1993-07-09 1994-07-08 Magnezium omeprazol
EP01117362A EP1164132A3 (fr) 1993-07-09 1994-07-08 Omeprazole de magnésium cristallin
HK98109227.9A HK1008329B (en) 1993-07-09 1994-07-08 Magnesium omeprazole
KR1019960700051A KR100353783B1 (ko) 1993-07-09 1994-07-08 마그네슘오메프라졸
CA002166794A CA2166794C (fr) 1993-07-09 1994-07-08 Derive magnesien d'omeprazole
YU43694A YU49193B (sh) 1993-07-09 1994-07-08 Magnezijum omeprazol i postupak za dobijanje ovog jedinjenja
SG1996004887A SG52464A1 (en) 1993-07-09 1994-07-08 A novel compound form
PCT/SE1994/000680 WO1995001977A1 (fr) 1993-07-09 1994-07-08 Omeprazole de magnesium
EE9400405A EE03127B1 (et) 1993-07-09 1994-11-17 Kristalne magneesiumomeprasool, selle valmistamise protsess, seda sisaldavad ravimpreparaadid ja nende kasutamine
DZ940071A DZ1792A1 (fr) 1993-07-09 1994-11-27 Une nouvelle forme de composé.
NO960068A NO308702B1 (no) 1993-07-09 1996-01-05 Magnesiumomeprazol, fremgangsmÕte for fremstilling derav, farmasøytisk preparat inneholdende magnesiumomeprazol og anvendelse derav
FI960101A FI114154B (fi) 1993-07-09 1996-01-09 Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi
GR970300015T GR970300015T1 (en) 1993-07-09 1997-05-30 Magnesium omeprazole
JP2001293480A JP3878826B2 (ja) 1993-07-09 2001-09-26 オメプラゾールマグネシウム

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Publications (1)

Publication Number Publication Date
SE9302396D0 true SE9302396D0 (sv) 1993-07-09

Family

ID=20390588

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Country Status (41)

Country Link
US (1) US5900424A (fr)
EP (2) EP0707580B1 (fr)
JP (2) JP3635432B2 (fr)
KR (1) KR100353783B1 (fr)
CN (1) CN1064680C (fr)
AT (1) ATE212628T1 (fr)
AU (1) AU679766B2 (fr)
BR (1) BR9406940A (fr)
CA (1) CA2166794C (fr)
CZ (1) CZ288933B6 (fr)
DE (2) DE69429774T2 (fr)
DK (1) DK0707580T3 (fr)
DZ (1) DZ1792A1 (fr)
EE (1) EE03127B1 (fr)
EG (1) EG21437A (fr)
ES (1) ES2100136T3 (fr)
FI (1) FI114154B (fr)
GR (1) GR970300015T1 (fr)
HR (1) HRP940385B1 (fr)
HU (1) HU226861B1 (fr)
IL (1) IL110190A (fr)
IS (1) IS2075B (fr)
MA (1) MA23257A1 (fr)
MX (1) MX9405217A (fr)
MY (1) MY113274A (fr)
NO (1) NO308702B1 (fr)
NZ (1) NZ268693A (fr)
PL (1) PL175999B1 (fr)
PT (1) PT707580E (fr)
RU (1) RU2139868C1 (fr)
SA (1) SA94150058B1 (fr)
SE (1) SE9302396D0 (fr)
SG (1) SG52464A1 (fr)
SI (1) SI0707580T1 (fr)
SK (1) SK281230B6 (fr)
TN (1) TNSN94079A1 (fr)
TW (1) TW504509B (fr)
UA (1) UA43343C2 (fr)
WO (1) WO1995001977A1 (fr)
YU (1) YU49193B (fr)
ZA (1) ZA944933B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
DK1078628T3 (da) 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) * 1998-04-22 2000-04-11 Torcan Chemical Ltd. Magnesium omeprazole and process for its preparation
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
US6403616B1 (en) 1998-11-18 2002-06-11 Astrazeneca Ab Chemical process and pharmaceutical formulation
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
CA2290893C (fr) 1999-11-16 2007-05-01 Bernard Charles Sherman Omeprazole de magnesium
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030212274A1 (en) * 2000-05-15 2003-11-13 Bakthavathsalan Vijayaraghavan Novel amorphous form of omeprazole salts
CA2386716C (fr) * 2002-05-17 2012-07-24 Bernard Charles Sherman Sel de magnesium de s-omeprazole
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
WO2003063840A2 (fr) * 2002-01-25 2003-08-07 Santarus, Inc. Administration par voie muqueuse d'inhibiteurs de la pompe a protons
FR2836228B1 (fr) * 2002-02-21 2005-08-19 Inst Francais Du Petrole Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
TWI367759B (en) * 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
WO2004099181A1 (fr) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Sel de baryum d'un derive de benzimidazole
CA2531564C (fr) * 2003-07-18 2016-01-19 Santarus, Inc. Formulations pharmaceutiques utilisees pour inhiber une secretion acide et procede de fabrication associe
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
RU2257890C2 (ru) * 2003-10-06 2005-08-10 Марио Атилио Лос Способ получения устойчивых фармацевтических композиций в форме таблеток, содержащих омепразол, и фармацевтические композиции, полученные таким способом
WO2005082888A1 (fr) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Procede de preparation d'un sel magnesique d'omeprazole
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US8658216B2 (en) 2004-12-23 2014-02-25 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
EP1845982A2 (fr) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Compositions de benzimidazole orales stables preparees par un procede de stratification non aqueux
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
EP1801110A1 (fr) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Sel d'arginine d'ésoméprazole
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
EP2046334B1 (fr) 2006-07-25 2014-05-21 Vecta Ltd. Compositions et procédés d'inhibition de sécrétion d'acide gastrique utilisant des dérivés de petits acides dicarboxyliques combinés á un ipp
CA2665226C (fr) 2006-10-05 2014-05-13 Santarus, Inc. Nouvelles formulations pour une liberation immediate d'inhibiteurs de pompe a protons et procedes d'utilisation de ces formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EP1947099A1 (fr) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Procédé pour l'élimination de solvant des sels d'oméprazole
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2009132980A1 (fr) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyle pyridones inhibiteurs de jnk
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
EP2147918A1 (fr) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Procédé de préparation de magnésium d'oméprazole S dans une forme stable
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
WO2010122583A2 (fr) 2009-04-24 2010-10-28 Rubicon Research Private Limited Compositions pharmaceutiques orales comprenant des substances labiles en milieu acide
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080500A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
EP2345408A3 (fr) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Formulations de médicament labiles acides
EP2601947A1 (fr) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Combinaison à dose fixe pour le traitement de maladies associées à Hélicobacter pylori
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
MY113274A (en) 2002-01-31
PT707580E (pt) 2002-06-28
IS4186A (is) 1995-01-10
NO308702B1 (no) 2000-10-16
NZ268693A (en) 1997-05-26
SK2296A3 (en) 1996-10-02
SK281230B6 (sk) 2001-01-18
DE707580T1 (de) 1997-09-04
AU7198194A (en) 1995-02-06
NO960068L (no) 1996-01-05
DE69429774D1 (de) 2002-03-14
CA2166794C (fr) 1997-03-04
HK1008329A1 (en) 1999-05-07
AU679766B2 (en) 1997-07-10
RU2139868C1 (ru) 1999-10-20
JPH08512315A (ja) 1996-12-24
HRP940385B1 (en) 2003-06-30
HUT75314A (en) 1997-05-28
FI114154B (fi) 2004-08-31
CZ6996A3 (en) 1996-05-15
IS2075B (is) 2005-12-15
GR970300015T1 (en) 1997-05-31
KR100353783B1 (ko) 2004-04-03
US5900424A (en) 1999-05-04
SI0707580T1 (en) 2002-06-30
EG21437A (en) 2001-10-31
EE03127B1 (et) 1998-10-15
EP1164132A2 (fr) 2001-12-19
BR9406940A (pt) 1996-09-10
IL110190A0 (en) 1994-10-21
JP2002105072A (ja) 2002-04-10
ES2100136T1 (es) 1997-06-16
EP1164132A3 (fr) 2002-01-02
EP0707580B1 (fr) 2002-01-30
HU9503873D0 (en) 1996-02-28
DZ1792A1 (fr) 2002-02-17
PL312440A1 (en) 1996-04-29
SA94150058B1 (ar) 2006-06-20
HRP940385A2 (en) 1997-02-28
FI960101A0 (fi) 1996-01-09
DE69429774T2 (de) 2002-11-14
ATE212628T1 (de) 2002-02-15
PL175999B1 (pl) 1999-03-31
FI960101L (fi) 1996-01-09
IL110190A (en) 2000-07-26
DK0707580T3 (da) 2002-04-15
UA43343C2 (uk) 2001-12-17
TNSN94079A1 (fr) 1995-04-25
SG52464A1 (en) 1998-09-28
EP0707580A1 (fr) 1996-04-24
ZA944933B (en) 1995-02-20
YU43694A (sh) 1997-07-31
NO960068D0 (no) 1996-01-05
TW504509B (en) 2002-10-01
CN1126993A (zh) 1996-07-17
JP3635432B2 (ja) 2005-04-06
WO1995001977A1 (fr) 1995-01-19
CZ288933B6 (cs) 2001-09-12
MA23257A1 (fr) 1995-04-01
MX9405217A (es) 1995-01-31
HU226861B1 (en) 2009-12-28
YU49193B (sh) 2004-09-03
CN1064680C (zh) 2001-04-18
JP3878826B2 (ja) 2007-02-07
ES2100136T3 (es) 2002-09-01

Similar Documents

Publication Publication Date Title
ATE212628T1 (de) Magnesium-omeprazol
HUT67653A (en) Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
CS38989A2 (en) Method of phenoxyacetamidoderivative production
NO179834C (no) Substituerte cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler
AU661591B2 (en) 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds
HU9201789D0 (en) Process for the production of substituted diamino-phtalimides and their analogues
AU1413788A (en) Dihydropyridinamides process for their preparation, and their use in medicaments
AU5778894A (en) Process for producing alkoxyiminoacetamide compounds and the production of intermediate compounds used in the process
HU904582D0 (en) Process for producing amino-oligohydroxi derivatives and pharmaceutical preparatives containing those compounds
JO1822B1 (en) A new form of a compound
HU913404D0 (en) Process for the production of medical compositions